Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001714899-22-000069
Filing Date
2022-04-19
Accepted
2022-04-19 16:03:11
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A a2022fy21defa14aproxy-defi.htm DEFA14A 10402
2 proxycard1.jpg GRAPHIC 124443
3 proxycard2.jpg GRAPHIC 109654
  Complete submission text file 0001714899-22-000069.txt   333836
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-38311 | Film No.: 22834978
SIC: 2836 Biological Products, (No Diagnostic Substances)